Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG00012 in pediatric RRMS
NCT02428218Phase 3Withdrawn
- Sponsor
- Biogen
- Start
- May 2016
- Primary completion
- Jan 2027
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Planned start May 2016; status: withdrawn.
02
Drugs
dimethyl fumarate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02428218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02428218.